GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » 3-Year EPS without NRI Growth Rate

NurExone Biologic (TSXV:NRX) 3-Year EPS without NRI Growth Rate : -28.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic 3-Year EPS without NRI Growth Rate?

NurExone Biologic's EPS without NRI for the three months ended in Dec. 2024 was C$-0.03.

During the past 3 years, the average EPS without NRI Growth Rate was -28.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of NurExone Biologic was -28.00% per year. The lowest was -28.00% per year. And the median was -28.00% per year.


Competitive Comparison of NurExone Biologic's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, NurExone Biologic's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's 3-Year EPS without NRI Growth Rate falls into.


;
;

NurExone Biologic 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


NurExone Biologic  (TSXV:NRX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


NurExone Biologic 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Industry
Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines